Info

🌱 來自：TAILORx

Summary-of-TAILORx

• The TAILORx trial showed that adjuvant endocrine therapy alone is → noninferior to chemoendocrine therapy in women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who have a midrange 21-gene recurrence score of 11 to 25.
• The two treatment groups had similar rates of invasive disease-free survival, freedom from disease recurrence, and overall survival.
• However, some benefit of chemotherapy was found in women 50 years of age or younger with a recurrence score of 16 to 25.

References

1. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | New England Journal of Medicine
2. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial | Breast Cancer | JAMA Oncology | JAMA Network